Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger
Earlier in the week, Novartis said it entered into an agreement with Avidity Biosciences, Inc.
Avidity Biosciences Inc. (RNA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 8,641,031 | $376,489,721 | +19% | 4.64% |
| 2. | VenBio Select Advisor Kurt Von Emster | 7,645,000 | $333,092,650 | +9% | 4.31% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,796,760 | $121,854,833 | +58% | 0.59% |
| 4. | Casdin Capital Eli Casdin | 1,780,000 | $77,554,600 | +1% | 6.47% |
| 5. | OrbiMed Advisors Samuel Isaly | 1,638,886 | $71,406,263 | -10% | 1.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 800,000 | $14,400,000.00 | 4,795,000 | 2021-08-04 | Filing | |
| $18.00 | 300,000 | $5,400,000.00 | 2,514,545 | 2020-06-16 | Filing | |
| $18.00 | 950,000 | $17,100,000.00 | 3,995,000 | 2020-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.54 | 2,209 | $105,014.53 | 38,867 | 2025-10-22 | Filing | |
| $50.15 | 20,000 | $1,003,058.00 | 97,130 | 2025-10-15 | Filing | |
| $45.38 | 6,562 | $297,771.09 | 55,000 | 2025-10-03 | Filing | |
| $40.58 | 2,208 | $89,600.64 | 38,867 | 2025-09-22 | Filing | |
| $41.41 | 15,000 | $621,142.50 | 97,130 | 2025-09-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,585,984 | $940,501,305 | 0.05% | |
| 2. | 14,522,915 | $632,808,722 | 0.29% | |
| 3. | 13,219,759 | $575,984,899 | 0.01% | |
| 4. | 11,372,829 | $495,514,160 | 6.11% | |
| 5. | 10,065,187 | $438,540,198 | 0.08% |
News See All
Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis
In a statement over the weekend, Novartis said that it entered into an agreement with Avidity Biosciences, Inc.
What Makes Avidity Biosciences (RNA) an Investment Choice?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating
In a market note, BofA Securities gave a “buy” recommendation for Avidity Biosciences Inc.’s (NASDAQ:RNA) stock with a price target of $65, an increase from the $56 previously.
11 Best Stocks to Buy for the Next 3 Months According to Hedge Funds
On September 6, Rebecca Patterson, Chief Investment Strategist at Bridgewater Associates, appeared in an interview on CNBC to discuss the current US economy.
Avidity (RNA) Gets 26% Jump on Potential Takeover
Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at $48.26 as investors gobbled up shares following reports that it received an acquisition bid from Swiss drugmaker...
Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation
Avidity Biosciences saw its share prices increase by 9.21 percent on Friday to end at $36.27 apiece as investor sentiment was bolstered by the Food and Drug Administration’s (FDA) breakthrough therapy...
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.